Feature

KULR Technology Group Inc. (NYSE: KULR) stock is undervalued. Or, better said, it’s disconnected from its fair value when appraising the value from its significant asset portfolio, well-protected IP, and contract visibility with some of the largest global conglomerates. And the KULR story isn’t just a forward-looking one. Recent operational performance has helped KULR score record-setting revenues, strengthen its balance sheet, and expand its market reach into several potentially lucrative lithium-Ion battery-safety markets.  In other words, with greater business depth

If there is one thing to know about KULR Technology Group Inc. (NYSE: KULR), it’s this- they have positioned themselves to dominate the lithium-Ion battery safety market. And the better news; results from that work are showing, with revenues scoring record levels, costs decreasing, and expansion of its innovative technology into several high-volume, high-dollar markets. In other words, while many viewed KULR as a premier play to get exposure into the massive EV battery safety market, they now have much

Mainz Biomed (NASDAQ: MYNZ) stock may present a value investment opportunity too good to ignore. In fact, a move higher is the likely path of least resistance for this thinly traded molecular genetics diagnostics company. They have a well-fortified balance sheet, best-in-class early cancer detection tests, and a management team that’s part of a Who’s Who list in biotech management fueling that proposition. But there’s more to validate that case. Like most smallcap biotechs in this turbulent market, MYNZ stock

Smallcap stocks may be under pressure. But not all are being pulled down by the decidedly bearish sentiment. Cosmos Health (NASDAQ: COSM), formerly Cosmos Holdings, is decoupling from the weakness and is doing so on merit, not hype. In fact, its recent 28% surge to $0.46 in September is supported by another batch of excellent news, which added to an already compelling value proposition resulting from several milestones reached earlier this year. These included a triple-digit percentage increase in EBITDA,

Cosmos Health (NASDAQ: COSM) stock is on the move. Rightly so. After its name change from Cosmos Holdings in July, the company has been on an operational roll, posting a triple-digit percentage increase in EBITDA, strong revenue growth, a significant milestone reached by its Sky Pharm SA subsidiary, and most importantly, positioned itself and its subsidiaries to perform exceptionally well into the end of 2022 and all of 2023. Of course, keep in mind that while its name is new,